Eli Lilly: Is the Buzz Justified?

by

Right. So, Eli Lilly. It’s been…a thing. A very expensive thing, actually. And one starts to wonder, doesn’t one? When a stock has basically rocketed into the stratosphere – up 400% in five years, honestly! – you begin to feel a slight tremor of panic. Is this still a sensible purchase, or am I about to catch a very expensive falling star? The valuation is…ambitious. Around 40 times earnings. Which, let’s be honest, feels a bit like buying a handbag that costs more than my car. But then again, maybe it’s worth it? This is the internal debate, endlessly replayed. Units of coffee consumed while researching: 7. Hours spent staring blankly at candlestick charts: approximately 11.

The thing is, everyone’s talking about it. Analysts are throwing around price targets like confetti. Which, admittedly, is helpful. But also slightly terrifying. Because analysts are, after all, human. And humans are prone to optimism. Or, sometimes, just plain wrongness. Still, it’s data. And data is…comforting. Sort of. I’ve been trying to be more data-driven. It’s a work in progress. Number of times I’ve ignored data in favour of ‘gut feeling’: uncountable.

Analysts Predict $1,221 – Seriously?

Apparently, the consensus is around $1,221. Which, if my calculations are correct (and they usually are, eventually), is a 35% upside from where it is now. 25 out of 30 ratings are ‘buy’. It’s…bullish. Very bullish. They’ve been upgrading their targets all year, fuelled by the success of Mounjaro and Zepbound. Those GLP-1 drugs. Everyone’s talking about weight loss. It’s a bit unsettling, actually. I mean, good for them, obviously, but it feels like the entire market is fixated on…injectables. Number of times I’ve considered investing in a gym: 3.

The last quarter was strong, too. Sales up 43%, net income up 50%. Which is…good. Obviously. But it’s also a bit…intimidating. It feels like a lot of pressure. If I buy now and it doesn’t go up, I’ll be the one looking foolish. The one who missed the boat. The one who should have listened to her mother and become an accountant.

Loading widget...

Is it a ‘No-Brainer’? Honestly?

Everyone keeps saying it’s a ‘no-brainer’. Which, frankly, is never a good sign. Nothing is ever a ‘no-brainer’ in investing. It’s all risk and uncertainty. But the analysts see plenty of room for growth. In the short term, at least. They’re projecting gains for the next 12 months. But what about the long term? That’s the really scary part. If Eli Lilly continues to dominate the GLP-1 market, it could deliver even stronger returns. But what if a competitor comes along? What if the drugs have unforeseen side effects? What if everyone suddenly decides that being slightly overweight is perfectly acceptable? (A girl can dream.)

It’s down 16% this year, which feels…significant. And it’s underperforming the S&P 500. Which is…disappointing. But I still think it’s a good long-term buy. It’s not cheap, admittedly. But it’s focused on growth, and it’s bringing new drugs to market. Which is…promising. I’m trying to build a portfolio, a sensible, diversified portfolio. It’s hard. So many shiny things. So many temptations. Number of impulse purchases made this week: 1 (a very expensive scented candle). But, yes. Eli Lilly. It might just be worth the premium. It might.

Read More

2026-03-23 16:03